METHOD OF PREVENTIVE ON-DEMAND HORMONAL CONTRACEPTION

1 . A method of hormonal female controlled on-demand contraception, characterized in that a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse.

2 . The method as claimed in claim 1 , characterized in that the pharmaceutical preparation is administered at the latest just prior to the first anticipated intercourse.

3 . The method as claimed in claim 2 , characterized in that the pharmaceutical preparation is administered no earlier than 12 hours prior to intercourse.

4 . The method as claimed in claim 1 , characterized in that the progestogen administered is selected from the group of compounds:

desogestrel,

etonorgestrel,

gestodene,

levonorgestrel or

trimegestone.

5 . The method as claimed in claim 4 , characterized in that the progestogen is released daily in an amount which results in endogenous progestogen levels which are equivalent in effect to endogenous gestodene levels developing after daily transdermal administration of 50 to 100 μg of gestodene.

6 . The method as claimed in claim 5 , characterized in that 50 to 100 μg of gestodene are administered daily.

7 . The method as claimed in claim 1 , characterized in that an estrogen is administered in addition.

8 . The method as claimed in claim 7 , characterized in that the estrogen administered is ethinylestradiol.

9 . The method as claimed in claim 8 , characterized in that the ethinylestradiol is administered in an amount which brings about a daily release of 10 to 30 μg of ethinylestradiol.

10 . A pharmaceutical preparation for use in any of the aforementioned methods as claimed in claim 1 .

11 . A transdermal patch comprising exclusively one, or more progestogens as active substance.

12 . The transdermal patch as claimed in claim 11 comprising gestodene as progestogen.

13 . The transdermal patch as claimed in claim 11 , from which an amount of progestogen equivalent in effect to 50 to 100 μg of gestodene is released.

14 . The transdermal patch as claimed in claim 11 having a size of 10 to 30 cm 2 .

15 . The transdermal patch as claimed in claim 11 , characterized in that the patch has a size of 10 to 20 cm 2 and that 50 to 100 μg of gestodene are released daily.

16 . (canceled)

17 . A pharmaceutical kit comprising at least one transdermal patch comprising one or more progestogens as active substance and optionally one or more estrogens, for carrying out a method as claimed in claim 1 , together with a product information leaflet describing the use of the patch in a method.